STOCKS TELEGRAPH

Author: Mahrukh Rehan

  • Zymeworks Inc. (ZYME) stock is going down in premarket – Why is that so?

    Zymeworks Inc. (ZYME) experienced a decrease of 13.63% in the premarket after the company announced a Pricing of $100.0 Million Public Offering. However, the last trading session closed at $9.32 with a decrease of 6.89%.

    $100.0 Million Public Offering – Recent News

    On 27 January 2022, ZYME announced the pricing of a $100 million public offering. Zymeworks will receive around $100.0 million in gross proceeds from the offering. This is the amount before eliminating underwriting discounts and charges, as well as other offering expenses. Moreover, ZYME has also given the underwriters a 30-day option to buy up to a maximum of 1,875,000 common shares just at the public offering price, after removing underwriting discounts and fees. Last but not the least, the offering will close on or around January 31, 2022.

    Corporate Update on Key Strategic Priorities by ZYME

    On 19th January 2022, ZYME presented a corporate update on its key strategic targets for 2022 and 2023, as well as verifying zanidatamab and ZW49 clinical development milestones. As a first step, ZYME has refocused the Company’s operations around the core functions and the most potential R&D prospects.

    These steps, including workforce reduction, offer the potential to lower future budgeted expenditures. The team is excited to report on the progress against these key priorities in 2022 and 2023 as they refocus, focus, and build a leading biopharmaceutical company around a renewed organization. The team will also report on the broadening pipeline of therapeutic compounds with the possibility to make a substantial difference for patients with difficult-to-treat cancers around the world.

    Corporate Update by ALX Oncology – More About it

    ALX Oncology issued a business update highlighting major milestones expected in 2022 on 10th January 2022. At ASH, researchers presented preliminary Phase 1a clinical data for evorpacept in conjunction with azacitidine in MDS patients (ASPEN-02). Moreover, the Phase 1 dose-expansion portion of the trial is still accumulating data. Not only this but ALX Oncology has acquired privately owned ScalmiBio, providing it full access to a unique SHIELD platform for conditional activation of antibodies in the tumor microenvironment and patented cytotoxic payloads for antibody-drug conjugates.

  • Evaxion Biotech A/S (EVAX) stock is jumping high in premarket – What’s happening?

    Evaxion Biotech A/S (EVAX) stock is jumping high in premarket – What’s happening?

    Evaxion Biotech A/S (EVAX) experienced an increase of 11.8% in the premarket today after the company announced the Publication of Clinical Data of EVX-01. However, the last trading session concluded at $3.22 with a decrease of 9.3%.

    Publication of Clinical Data of EVX-01 – All About it

    On 26th January 2022, EVAX announced that the open-access journal OncoImmunology recently published an article on therapy with EVX-01 in patients with metastatic melanoma. The results of the study’s five participants showed that EVX-01 is safe and offers promising early signs of clinically relevant anticancer efficacy. In a clinical context where patients were receiving standard immune therapy, data showed that EVX-01 was capable of triggering T-cell responses.

    The results showed that anti-PD-1 medication combined with anti-tumor treatment had an anticancer impact. Furthermore, in a planned Phase 2b research, Evaxion will assess the efficacy and safety of EVX-01 in combination with KEYTRUDA (pembrolizumab). It is an anti-PD1 medication, in approximately 100 persons with unresectable or metastatic melanoma. The main objective will be the overall response.

    What’s Next?

    Neoantigen-based personalized immunotherapy is a promising cancer treatment strategy. PIONEER’s great promise in producing completely tailored immunotherapies to improve therapy for patients with melanoma. Last but not the least, the company is thrilled to have the funds to pursue EVX-01’s potential in the new Phase 2b trial, which EVAX intends to begin in Q2 2022 in conjunction with Merck.

    Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 – Latest News by EVAX

    On 18th January 2022, EVAX reported that Australia Therapeutic Goods Administration has approved the start of a Phase 2b trial. The approval of the Phase 2b study of the main medicine is a major step forward for Evaxion. Data from the Phase 1/2a trial suggest that EVX-01 could significantly enhance the therapy landscape for melanoma. Last but not the least, combining EVX-01 with checkpoint inhibitors like KEYTRUDA could provide further advantages.

  • DouYu International Holdings Limited (DOYU) Stock Rising in Premarket, Here’s The Latest News

    DouYu International Holdings Limited (DOYU) has seen an increase of about 10% in premarket after reports that one of the biggest shareholders Tencent Holdings Tencent, having 37% shares in the company, wants to take it private. The reason behind this is said to be disagreements between its executives over strategy. Tencent is reportedly in discussion with investment banks about partnering with at least one private equity firm. However, the last trading session closed at $2.21 with a decrease of 1.78%.

    Changes in Board of Directors by DOYU – What’s up?

    DOYU announced certain changes in the Board of Directors on 7th December 2021. Mr. Wenming Zhang has resigned as a director and co-chief executive officer of DOYU. Ms. Yang Deng started at DouYu as legal director in August of 2015 and has been vice president of legal affairs since February of 2017. From 2013 to 2015, Ms. Deng worked as a senior in-house lawyer at Vipshop Holdings Limited, China’s largest online discount retailer. Moreover, Ms. Deng formerly worked as a legal specialist for Xunlei Limited which is a Chinese company.

    So what?

    On behalf of the Board and DOYU, Wenming has been congratulated for his outstanding service. Furthermore, the team congratulates him on his accomplishments and wishes him the best of luck in his future endeavors. Moreover, the firm has happily announced Yang’s appointment as a director and Mingming’s appointment as a member of the Board’s pay, nominating, and governance procedures.

    Furthermore, as a leading game-centric live streaming platform in China and a pioneer in the eSports value chain, everyone on the team is dedicated to upholding the highest standards of corporate governance. Last but not least, the business is certain that Yang and Mingming will make a substantial contribution to DouYu’s future growth in their new roles on the Board.

    Third Quarter 2021 Financial Results by DOYU– How was the quarter?

    DOYU reported third-quarter results on 16th November 2021. The company reported net revenues of US$364.4 million and a gross profit of US$43.2 million. Not only this but a net loss of US$22.3 million has also been reported along with the adjusted net loss of US$11.3 million by DOYU. Lastly, Mobile MAUs climbed to 61.9 million in the third quarter of 2021.

    What’s Next?

    In the third quarter of 2021, the fundamental operating metrics continued to improve steadily. Moreover, DOYU intends to broaden the gaming genres and content offerings in the future. By leveraging the unique marketing methods, the team will transform DouYu into a manufacturing game-centric content ecosystem. 

  • ServiceNow, Inc. (NOW) stock is jumping high in premarket – What’s the reason?

    ServiceNow, Inc. (NOW) experienced an increase of 10% in the premarket after the company announced the fourth quarter and full-year 2021 financial results. However, the last trading session closed at $ 484.42 with a decrease of 2.15%.

    Fourth Quarter & Full Year 2021 Financial Results – Latest News

    NOW announced full-year 2021 and fourth-quarter results on 26th January 2022. The subscription revenue came out to be $1,523 million with 29% year-over-year growth. Moreover, there were $5.7 billion in remaining performance obligations. Not only this but there were 135 deals for more than $1 million in net new annual contract value, marking a 52 percent increase year over year. Last but not the least, NOW beats the high end of forecast across the board in Q4 2021 with constant currency subscription revenue growth accelerating year-over-year in Q1 2022.

    Now what?

    The fourth quarter was a standout quarter that capped off a stellar year of earnings growth. The company is working hard, and the company is looking forward to a fantastic year in 2022. In addition, the company expects constant currency subscription revenue growth to increase year over year, positioning the firm for the next solid year and keeping them on track to become a $15 billion revenue company.

    Executive Leadership Promotions by NOW – What’s up?

    On 26th January 2022, NOW announced worldwide executive team promotions. Chirantan CJ Desai, the company’s chief product and engineering officer, is the chief operating officer (COO) now. Moreover, Kevin Haverty, the company’s chief revenue officer, has been appointed to the position of senior advisor to the CEO. Not only this but Paul Smith, the president of EMEA, has been appointed as the chief commercial officer. ServiceNow continues to dominate and collaborate with clients to help them advance their digital transformations. In addition, the company has a tremendous opportunity of becoming the platform for every business, ministry, and educational institution on the planet. Bringing the product and industry sales teams under one roof is in line with the customer-first philosophy and will allow the company to expedite the development cycles even further.

    What’s Next?

    NOW is increasing the leadership team in preparation for scalability as the business grows. Furthermore, customers have never been more interested in ServiceNow’s cutting-edge platform. They couldn’t be more confident in the path to $15 billion in revenue and beyond, with individuals of this level.

  • Seagate Technology Holdings plc (STX) stock is on rise – Learn why?

    Seagate Technology Holdings plc (STX) experienced an increase of 6.95% in the aftermarket following the announcement of fiscal second-quarter 2022 results and a new appointment to its BoD. However, the last trading session closed at $96.31 with an increase of 1.61%.

    Fiscal Second Quarter 2022 results by STX – What’s new?

    STX announced fiscal second-quarter 2022 results on 26th January 2022. The company reported net revenue of $3.12 billion. Moreover, the cash flow from operations was $521 million with a GAAP operating margin of 18.6%. Seagate had a great year in the calendar year 2021. The company noticed increased revenue by 18% year over year. The company achieved a 39 percent increase in free cash flow, which we are putting to good use in the long-term capital return program.

    Now what?

    The calendar year was closed off with a robust December quarter, which saw the company achieve the best revenue level in over six years. This was possible because of a cloud data center interest for the larger capacity nearline products. With positive demand trends supporting revenue expansion consistent with the long-term financial model range of 3-to-6 percent annual growth, the company looks to improve on the 2021 performance this calendar year and beyond, assuming any substantial new economic challenges.

    Appointment of Yolanda Lee Conyers by STX – More About it

    On 25th January 2022, STX announced that the company has appointed Yolanda Lee Conyers to the board of directors. Ms. Conyers has worked in roles ranging from technology to global operations to talent management for more than 30 years. Moreover, she oversaw Lenovo’s human resources strategy and advised various executive members of the committee.

    The company is very happy to welcome Yolanda to the Board of Directors. Yolanda is a well-known global human resource leader with experience in organizational and leadership development. Furthermore, her vast technology sector experience and considerable knowledge will be a valuable addition to the Seagate board of directors, and she will assist the efforts to build a more diverse and inclusive workforce to create successful business outcomes.

  • Edwards Lifesciences Corporation (EW) stock has seen a decrease of 5.74% – Here’s why?

    Edwards Lifesciences Corporation (EW) experienced a decrease of 5.74% in the aftermarket after the company announced fourth-quarter results. However, the last trading session concluded at $108.63 with a decrease of 0.79%.

    Fourth Quarter Results by EW – What’s up?

    EW reported fourth-quarter results on 26th January 2022. The company stated that they have seen a 19% increase in the 2021 sales. Not only this but Q4 sales also inclined to $1.33 billion with the growth of almost 12%. Moreover, the selling, general, and administrative expenses totaled $424 million, $339 million more than that of the previous year. In comparison to the COVID, this growth was motivated by the return of medical congresses and commercial activities. Last but not the least, the research and development expenses also increased 19 percent to $233 million.

    So what?

    EW sees even greater growth and progress in 2022. The business is optimistic about the continued spread of transcatheter-based therapies for the many structural heart patients who still require them, putting them in a good position for long-term success. As the world’s population ages and the cardiovascular disease continues to be the main cause of death, EW predicts that the chance to service patients will nearly double between now and 2028. Finally, the organization is optimistic about the possibility of a patient-centered innovation strategy to transform treatment.

    FDA Approval for Sapien 3 – More About it

    On 20th December 2021, EW announced that FDA has authorized the use of the Edwards SAPIEN 3 transcatheter valve. The FDA’s authorization of the SAPIEN 3 with Alterra is fantastic news for patients all over the world, including those who have had multiple surgeries to treat their congenital heart defects.

    Moreover, the excellent results of SAPIEN 3 with Alterra will broaden the number of patients requiring pulmonary valve replacement. Lastly, this will lead to major improvements in quality of life as well as a decrease in the number of surgeries and treatments that a congenital heart patients will require during their lifespan.

  • Teradyne, Inc. (TER) stock is going down in aftermarket – What’s the reason?

    Teradyne, Inc. (TER) experienced a decrease of 20.14% in the aftermarket following the announcement of fourth quarter and fiscal year 2021 results. However, the last trading session closed at $ 143.37 with increase of 3.67%.

    Fourth Quarter and Fiscal Year 2021 results by TER

    On 26th January 2022, TER announced fourth quarter and fiscal year 2021 results. According to the report, the revenue came out to be $885 million. Not only this but the company also reported net income of $238.4 million. In addition, in 2022, TER plans to buyback a minimum of $750 million in ordinary shares. The test and industrial technology businesses both generated another quarter of double-digit sales increase when compared to the prior year.

    Furthermore, TER boosted yearly revenues by 19% and non-GAAP earnings per share by 29 percent in 2021. This capped a five-year span in which revenue and earnings climbed at yearly rates of 16% and 32%, respectively. Last but not the least, the Universal Robots and MiR businesses, in particular, are experiencing strong demand, resulting in a 40% increase in revenue in 2021.

    What’s Next?

    The company has raised the mid-point of the revenue and non-GAAP profits per share expectations in 2024 earnings model to $4.9 billion and $8.00, respectively. However, TER predicts a slower technology shift in one of the major end markets in 2022 to result in reduced Teradyne System-on-a-Chip test demand, which will then accelerate during the 3nm production ramp in 2023. On the strength of favourable global economic trends and the significant value of automation technologies, the company expects strong substantial growth in Industrial Automation in 2022.

    Third Quarter Results 2021 – Latest Stats by TER

    On 28th October 2021, TER announced third quarter 2021 results. The company has experienced the revenue of about $951 million. Not only this but the income in third quarter came out to be $278.6 million. Moreover, demand for both the Test and Industrial Automation products remained robust in Q3. And the company delivered the eighth quarter of double-digit year-over-year profitability increase.

    Now what?

    On increased supply in Industrial/Automotive Test, Storing Test, and Industrial Automation, Q4’21 sales are predicted to expand by more than 10% from Q4 2020’s historical high. Moreover, at the mid-point of the projection, full-year company sales, GAAP EPS, and non-GAAP EPS are expected to climb 18 percent, 28 percent, and 27 percent, respectively.

  • Vinco Ventures, Inc. (BBIG) stock is jumping high – What’s going on?

    Vinco Ventures, Inc. (BBIG) experienced an increase of 19.27% in the aftermarket despite the fact that McFillin Phillip Anthony sold 100,000 shares at a cost of $5 per share according to the SEC filing. However, the last trading session concluded at $3.01 with an increase of 2.73%.

    Third Quarter 2021 Financial Results – How was BBIG’s quarter?

    BBIG announced the third-quarter results of 2021 on 22nd November 2021. The company reported cash and cash equivalents of $149.9 million whereas the revenue was $2.23 million from $2.52 million. Moreover, there was a sudden decrease noticed in the gross profit margin when it declined to 31.4%. The drop is mostly due to a drop in safety equipment sales in the Edison Nation Medical segment. Furthermore, selling, general and administrative expenses came out to be $25.9 million. Last but not the least, BBIG experienced a net loss of $542.5 million.

    Operational Results by BBIG – More About it

    BBIG reported a joint venture with ZASH Global Media and Entertainment Corporation. It has acquired an 80 percent shareholding in Lomotif Private Limited. Moreover, Lomotif collaborated with EDC Las Vegas to launch the Lomotif brand in the United States. Lomotif engaged over 150 influencers, resulting in over 51 million TikTok views and over 40 million Instagram story views for the Lomotif brand. Last but not the least, ZVV completed its first TV series, Preach, and its first feature picture, Camp Hideout, as a result of its business partnership with Zash.

    Partnership with EDC Las Vegas – Worth it?

    On 12 November 2022, it was announced that Lomotif used its collaboration with EDC Las Vegas as a staging ground in the US cultural scene, with plans to launch in the United States in 2022. Lomotif’s largest domestic effort to date to spread awareness of the Lomotif platform was the EDC activation and alliance. Moreover, Lomotif experimented with cross-pollination between Lomotif and other prominent social media platforms, such as TikTok and Instagram.

    What’s New?

    Lomotif thinks that AdRizer, their social media accelerator, would enable scalable revenue via social media reach and frequency. Users will be able to buy advertising for as little as $5 each to improve their personal pages, and small companies will be able to market to hyper-targeted demographics. In addition, advertisers on Lomotif should be able to decide how often their ads are provided to different target audiences.

  • Sierra Oncology, Inc. (SRRA) stock is jumping high – What’s going on?

    Sierra Oncology, Inc. (SRRA) stock is jumping high – What’s going on?

    Sierra Oncology, Inc. (SRRA) has seen an increase of 64.15% in the premarket after the company announced a financial update to Support the Commercialization of Momelotinib. However, the last trading session concluded at $15.51 with a decrease of 8.06%.

    Commercialization of Momelotinib – What’s up?

    On 25th January 2022, SRRA reported that it has signed a term loan agreement with Oxford Finance. This will help in funding the commercialization and eventual launch of momelotinib. As the company extends work toward an NDA submission and eventual approval of momelotinib, a solid cash position, along with the term loan agreement with Oxford, gives them a lot of financial flexibility.

    Phase 3 MOMENTUM study Data Revealed!

    SRRA reported phase 3 Momentum Study data on 25th January 2022. The company is ecstatic to see data confirming momelotinib’s potential as a treatment option for anemic or at-risk myelofibrosis patients. At the time of diagnosis, half of all myelofibrosis patients have anemia, and almost all become anemic over time. Given that the majority of presently authorized medications are myelosuppressive, it’s exciting to think that these patients may have such a powerful therapy choice very soon.

    Topline Data Timing – What’s happening?

    SRRA announced on 18th January 2022 that the company is planning to release the topline data sooner than expected. Hopefully, SRRA will release the stats by the end of January 2022.  Everyone is excited to know about the facts and figures related to the Phase 3 study because it costs a lot of team effort. Not only this but the team is dedicated to getting this potential drug to myelofibrosis patients, especially those with anemia, as soon as possible.

    About SRRA

    SRRA is a late-stage biopharmaceutical company that is dedicated to developing and commercializing targeted cancer therapies for patients suffering from rare tumors. Moreover, they apply comprehensive scientific expertise to develop molecules that treat the disease’s fundamental cause. To better understand the limitations of current treatments the team uses an evidence-based approach. Last but not the least, they are collaborating to help patients transform their potential into reality.

  • Reviva Pharmaceuticals Holdings, Inc. (RVPH) stock is down in premarket – Here’s why?

    Reviva Pharmaceuticals Holdings, Inc. (RVPH) experienced a decrease of 6.38% in the premarket. However, the last trading session concluded at $1.88 with an increase of  8.67%.

    Letter for Pivotal Phase 3 Clinical Trial – Latest Updates by RVPH

    On 10th January 2022, RVPH announced that brilaroxazine has been approved by the US Food and Drug Administration (FDA). It is a critical milestone, that might contribute to the registration and approval of new medicine for use in schizophrenia patients. Furthermore, long-term safety studies will improve the essential trial’s favorable safety data. Finally, RVPH remains confident about the therapeutic potential of brilaroxazine and expects to begin Phase 3 analysis by the end of January 2022.

    About Brilaroxazine

    Reviva Pharmaceuticals is developing brilaroxazine, commonly known as oxaripiprazole, as an experimental antipsychotic for the treatment of schizophrenia and schizoaffective disorder. It is highly specific because of major serotonin and dopamine receptors linked to schizophrenia and related symptoms. In addition, it has undergone a comprehensive series of regulatory-compliant toxicity and safety pharmacology tests.

    Third Quarter 2021 Financial Results by RVPH – What’s new?

    RVPH stated third quarter 2021 financial results on 15th November 2021. The net loss came out to be $2.28 million. Moreover, the Company’s cash balance was $33.5 million, $0.35 million more than the previous quarter. Not only this but the company hired a clinical research firm. This was done to oversee the recruiting and trial services for its crucial Phase 3 studies.

    In addition, the company is planning to launch a major Phase 3 study examining the efficacy and safety of brilaroxazine. Lastly. the regulatory applications for the start of Phase 2 studies in pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) ought to be completed by the end of Q1 2022.

    Now what?

    RVPH plans to begin two Phase 3 studies to evaluate the brilaroxazine in people with schizophrenia, as well as long-term safety. The company might do it before the end of the year. Furthermore, depending on the therapeutic potential of brilaroxazine, the firm aims to file marketing applications with the FDA.